ADCT
ADC Therapeutics SA
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
-1/100
Last price
1.27
▲ 0.04 (3.25%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.23
Day high
1.27
Day low
1.20
Volume
1.35M
Market cap
$162.14M
P/E (TTM)
—
52W range
0.78 – 4.98
Trailing performance
Returnvs SPY
1W
+3.25%
+1.3%
1M
-6.62%
-7.8%
3M
-0.78%
-5.3%
6M
-65.86%
-84.0%
YTD
-64.02%
-78.3%
1Y
-68.87%
-85.3%
3Y
+41.58%
-40.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ADCT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
18.41M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | GRAHAM PETER J Officer |
STOCK | 221.10K | $0 | Direct |
| Jun 30, 26 | CARMONA JOSE Chief Financial Officer |
STOCK | 203.70K | $0 | Direct |
| Jun 30, 26 | MALLIK AMEET Chief Executive Officer |
STOCK | 675.00K | $0 | Direct |
| Jun 30, 26 | ZAKI MOHAMED Officer |
STOCK | 213.90K | $0 | Direct |
| Jun 1, 26 | COUGHLIN TIMOTHY P Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | SQUARER RON R Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | BIZZARI JEAN-PIERRE Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | SANDOR VICTOR Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | AZELBY ROBERT W Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | MONGES VIVIANE Director |
STOCK | 45.00K | $0 | Direct |
| Jun 1, 26 | HUG PETER Director |
STOCK | 45.00K | $0 | Direct |
| Apr 2, 26 | REDMILE GROUP, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 5.88M | $19.64M | Indirect |
| Feb 13, 26 | GRAHAM PETER J Officer |
STOCK | 294.80K | $1.18M | Direct |
| Feb 13, 26 | CARMONA JOSE Chief Financial Officer |
STOCK | 271.60K | $1.08M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BIZZARI JEAN-PIERRE |
Director | 139.30K | Stock Award(Grant) |
CARMONA JOSE |
Chief Financial Officer | 938.08K | Stock Award(Grant) |
GRAHAM PETER J |
Officer | 841.64K | Stock Award(Grant) |
HUG PETER |
Director | 263.34K | Stock Award(Grant) |
KALLEBO LISA MICHELLE |
Officer | 128.22K | Stock Award(Grant) |
MALLIK AMEET |
Chief Executive Officer | 2.12M | Stock Award(Grant) |
MONGES VIVIANE |
Director | 186.45K | Stock Award(Grant) |
REDMILE GROUP, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
SANDOR VICTOR |
Director | 140.69K | Stock Award(Grant) |
ZAKI MOHAMED |
Officer | 896.32K | Stock Award(Grant) |
Fundamentals
Market cap$162.14M
Enterprise value$381.22M
Revenue (TTM)$79.58M
Gross profit$-9.23M
EBITDA$-93.71M
Net income$-96.91M
EPS (TTM)$-0.60
Free cash flow$-68.12M
Total cash$219.11M
Total debt$438.19M
Book value / share$-1.79
Shares outstanding127.67M
Float88.56M
Short % of float4.98%
Dividend yield0.00%
Beta (5Y)1.86
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.85
PEG ratio—
Price / sales—
Price / book—
EV / revenue4.79
EV / EBITDA-4.07
Gross margin-11.59%
Operating margin-118.14%
Profit margin-121.77%
Return on equity—
Return on assets-19.57%
Debt / equity—
Current ratio3.03
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $81.36M | $70.84M | $69.56M | $209.91M | +14.9% |
| Operating revenue | $81.36M | $70.84M | $69.56M | $209.91M | +14.9% |
| Cost of revenue | $5.80M | $5.95M | $2.53M | $3.30M | -2.5% |
| Gross profit | $75.56M | $64.89M | $67.03M | $206.61M | +16.4% |
| Research & development | $104.00M | $109.63M | $127.13M | $186.46M | -5.1% |
| Selling, general & admin | $79.93M | $85.91M | $105.89M | $143.49M | -7.0% |
| Total operating expense | $182.77M | $194.48M | $232.08M | $329.59M | -6.0% |
| Operating income | -$107.21M | -$129.59M | -$165.05M | -$122.99M | +17.3% |
| Net interest income | -$42.82M | -$37.94M | -$35.78M | -$34.16M | -12.9% |
| Pre-tax income | -$141.61M | -$156.14M | -$195.42M | -$146.82M | +9.3% |
| Tax provision | $1.01M | $166.00K | $39.11M | $227.00K | +511.4% |
| Net income | -$142.62M | -$157.85M | -$240.05M | -$157.13M | +9.6% |
| Net income to common | -$142.62M | -$157.85M | -$240.05M | -$157.13M | +9.6% |
| Basic EPS | -1.12 | -1.62 | -2.94 | -1.99 | +30.9% |
| Diluted EPS | -1.12 | -1.62 | -2.94 | -1.99 | +30.9% |
| EBIT | -$89.97M | -$105.92M | -$149.09M | -$110.09M | +15.1% |
| EBITDA | -$88.10M | -$102.65M | -$145.83M | -$107.70M | +14.2% |
| Basic shares | 127.07M | 97.16M | 81.71M | 78.15M | +30.8% |
| Diluted shares | 127.07M | 97.16M | 81.71M | 78.15M | +30.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $261.34M | $250.87M | $278.60M | $326.44M | — | +4.2% |
| Cash & short-term investments | $261.34M | $250.87M | $278.60M | $326.44M | — | +4.2% |
| Accounts receivable | $29.12M | $20.32M | $25.18M | $72.97M | — | +43.3% |
| Inventory | $4.18M | $2.25M | $16.18M | $12.07M | — | +85.9% |
| Total current assets | $306.33M | $291.25M | $336.29M | $434.98M | — | +5.2% |
| Property, plant & equipment | $1.30M | $13.43M | $16.13M | $10.26M | — | -90.3% |
| Goodwill & intangibles | — | — | — | $14.36M | $13.58M | — |
| Total assets | $323.15M | $321.98M | $354.78M | $490.86M | — | +0.4% |
| Total current liabilities | $70.16M | $80.47M | $67.67M | $81.94M | — | -12.8% |
| Current debt | $3.00M | — | — | $12.47M | $6.58M | — |
| Long-term debt | $112.45M | $113.63M | $112.73M | $109.71M | — | -1.0% |
| Total debt | $117.02M | $123.00M | $124.38M | $117.38M | — | -4.9% |
| Total liabilities | $508.98M | $524.62M | $503.03M | $411.41M | — | -3.0% |
| Retained earnings | -$1.64B | -$1.49B | -$1.34B | -$1.10B | — | -9.6% |
| Shareholder equity | -$185.83M | -$202.64M | -$148.25M | $79.45M | — | +8.3% |
| Working capital | $236.17M | $210.78M | $268.62M | $353.04M | — | +12.0% |
| Net tangible assets | -$185.83M | -$202.64M | -$148.25M | $79.45M | — | +8.3% |
| Shares issued | 128.31M | 101.61M | 89.04M | 89.04M | — | +26.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$142.62M | -$157.85M | -$240.05M | -$157.13M | — | +9.6% |
| Depreciation & amortisation | $1.88M | $3.28M | $3.27M | $2.39M | — | -42.7% |
| Stock-based compensation | $6.91M | $6.57M | $13.49M | $49.32M | — | +5.1% |
| Change in working capital | -$25.36M | $3.83M | $44.27M | -$48.73M | — | -762.7% |
| Operating cash flow | -$141.17M | -$123.83M | -$118.69M | -$138.31M | — | -14.0% |
| Capital expenditure | -$264.00K | -$867.00K | -$3.22M | -$687.00K | — | +69.6% |
| Investing cash flow | $395.00K | -$867.00K | -$3.22M | -$687.00K | — | +145.6% |
| Share buybacks | — | — | — | -$221.00K | $0 | — |
| Financing cash flow | $150.94M | $97.05M | $73.88M | -$897.00K | — | +55.5% |
| Free cash flow | -$141.44M | -$124.70M | -$121.90M | -$139.00M | — | -13.4% |
| End cash position | $261.34M | $250.87M | $278.60M | $326.44M | — | +4.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $19.25M | $20.85M | $23.06M | $16.43M | $18.84M | -7.7% |
| Operating revenue | $19.25M | $20.85M | $23.06M | $16.43M | $18.84M | -7.7% |
| Cost of revenue | $2.35M | $3.62M | $1.70M | $1.20M | $836.00K | -35.0% |
| Gross profit | $16.90M | $17.24M | $21.36M | $15.22M | $18.00M | -2.0% |
| Research & development | $17.37M | $19.88M | $18.18M | $26.80M | $30.09M | -12.6% |
| Selling, general & admin | $22.27M | $22.60M | $21.44M | $19.01M | $18.97M | -1.5% |
| Total operating expense | $39.68M | $42.48M | $39.48M | $45.55M | $48.58M | -6.6% |
| Operating income | -$22.78M | -$25.25M | -$18.12M | -$30.33M | -$30.57M | +9.8% |
| Net interest income | -$11.69M | -$10.36M | -$10.66M | -$10.92M | -$11.06M | -12.9% |
| Pre-tax income | -$16.57M | -$32.97M | -$6.81M | -$40.97M | -$55.39M | +49.8% |
| Tax provision | $0 | $0 | -$404.00K | $0 | $1.25M | — |
| Net income | -$16.57M | -$32.97M | -$6.41M | -$40.97M | -$56.65M | +49.8% |
| Net income to common | -$16.57M | -$32.97M | -$6.41M | -$40.97M | -$56.65M | +49.8% |
| Basic EPS | -0.11 | -0.21 | -0.04 | -0.30 | -0.50 | +47.6% |
| Diluted EPS | -0.11 | -0.21 | -0.04 | -0.30 | -0.50 | +47.6% |
| EBIT | -$3.06M | -$20.62M | $6.20M | -$27.57M | -$42.40M | +85.2% |
| EBITDA | -$3.06M | -$20.50M | $6.31M | -$27.57M | -$42.40M | +85.1% |
| Basic shares | 155.02M | 154.14M | 150.30M | 136.45M | 113.74M | +0.6% |
| Diluted shares | 155.02M | 154.14M | 150.30M | 136.45M | 113.74M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $219.11M | $231.01M | $261.34M | $234.74M | $264.56M | -5.2% |
| Cash & short-term investments | $219.11M | $231.01M | $261.34M | $234.74M | $264.56M | -5.2% |
| Accounts receivable | $28.04M | $31.05M | $29.12M | $22.92M | $26.18M | -9.7% |
| Inventory | $4.93M | $4.78M | $4.18M | $18.04M | $17.76M | +3.3% |
| Total current assets | $261.71M | $276.77M | $306.33M | $287.15M | $318.75M | -5.4% |
| Property, plant & equipment | $1.10M | $1.20M | $1.30M | $1.39M | $1.49M | -8.3% |
| Total assets | $279.38M | $291.50M | $323.15M | $289.76M | $321.56M | -4.2% |
| Total current liabilities | $86.33M | $67.63M | $70.16M | $62.04M | $64.60M | +27.7% |
| Current debt | $6.18M | $4.63M | $3.00M | — | — | +33.3% |
| Long-term debt | $110.44M | $111.04M | $112.45M | $115.21M | $114.47M | -0.5% |
| Total debt | $117.56M | $116.67M | $117.02M | $117.27M | $117.52M | +0.8% |
| Total liabilities | $507.58M | $507.87M | $508.98M | $527.94M | $520.75M | -0.1% |
| Retained earnings | -$1.69B | -$1.67B | -$1.64B | -$1.63B | -$1.59B | -1.0% |
| Shareholder equity | -$228.21M | -$216.38M | -$185.83M | -$238.18M | -$199.18M | -5.5% |
| Working capital | $175.38M | $209.14M | $236.17M | $225.10M | $254.16M | -16.1% |
| Net tangible assets | -$228.21M | -$216.38M | -$185.83M | -$238.18M | -$199.18M | -5.5% |
| Shares issued | 127.44M | 129.73M | 128.31M | 115.19M | 115.08M | -1.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$16.57M | -$32.97M | -$6.41M | -$40.97M | -$56.65M | — | +49.8% |
| Depreciation & amortisation | — | $114.00K | $113.00K | $122.00K | $1.18M | $459.00K | — |
| Stock-based compensation | $4.55M | $2.44M | $673.00K | $2.00M | $1.81M | — | +86.3% |
| Change in working capital | $12.33M | -$5.00M | -$11.58M | $392.00K | $15.35M | — | +346.4% |
| Operating cash flow | -$11.81M | -$29.71M | -$31.12M | -$29.63M | -$24.09M | — | +60.3% |
| Capital expenditure | — | -$32.00K | — | — | — | -$264.00K | — |
| Investing cash flow | $0 | -$32.00K | $659.00K | $0 | $0 | — | +100.0% |
| Share buybacks | $0 | -$20.00K | — | — | — | $0 | +100.0% |
| Financing cash flow | -$99.00K | -$583.00K | $57.09M | -$198.00K | $93.78M | — | +83.0% |
| Free cash flow | -$11.81M | -$29.74M | -$31.12M | -$29.63M | -$24.09M | — | +60.3% |
| End cash position | $219.11M | $231.01M | $261.34M | $234.74M | $264.56M | — | -5.2% |
Options analytics
Put / call volume
0.19
Call-heavy session
Put / call open interest
0.45
Positioning, not flow
Max pain
5.00
+293.7% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
191
Contracts, this expiry
Put volume
36
Contracts, this expiry
Heaviest call OI
7.50
66 contracts
Heaviest put OI
5.00
30 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.22 | -0.11 | +49.1% |
| Mar 2026 | -0.20 | -0.21 | -4.1% |
| Dec 2025 | -0.27 | -0.04 | +85.1% |
| Sep 2025 | -0.36 | -0.30 | +17.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.21 | 5 | $18.86M | +14.8% |
| Next quarter | -0.20 | 5 | $22.07M | -4.3% |
| Current year | -0.76 | 4 | $80.65M | -0.9% |
| Next year | -0.68 | 4 | $101.96M | +26.4% |
Analyst targets & ownership
Mean target$3.33
High target$5.00
Low target$2.00
Implied upside162.47%
Analyst count3
ConsensusNONE
Strong buy / Buy0 / 3
Hold2
Sell / Strong sell0 / 0
Held by insiders14.42%
Held by institutions67.56%
Institutions holding150
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.23
+3.34% from price
SMA 20
1.17
+8.55% from price
SMA 50
1.14
+11.40% from price
SMA 100
1.45
-12.59% from price
SMA 200
2.67
-52.37% from price
EMA 12
1.20
+5.74% from price
EMA 26
1.19
+7.13% from price
EMA 50
1.25
+1.89% from price
RSI (14)
56.3
Neutral
MACD (12,26,9)
0.02
Hist 0.00
ATR (14)
0.10
7.68% of price
Realised vol 30D
81.6%
Annualised
Bollinger upper
1.35
20, 2σ
Bollinger lower
0.99
20, 2σ
50 / 200 cross
Death
1.14 vs 2.67
Trend bias
Below 200
-52.37%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.32
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
81.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-80.3%
Peak to trough
Max drawdown 5Y
-98.5%
Peak to trough
ATR 14
0.10
7.68% of price
Beta (reported)
1.86
5Y monthly, from filing
Short interest
Shares short
5.39M
Prior 6.18M
Change vs prior
-12.7%
Shorts covering
% of float
4.98%
Normal
% of shares out
4.22%
Against total outstanding
Days to cover
3.0
Liquid
Float
88.56M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jun 8, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jun 4, 26 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| May 5, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 5, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 16, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 13, 25 | Guggenheim | MAINTAINED | Buy | Buy |
| Jun 20, 25 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jun 13, 25 | Guggenheim | MAINTAINED | Buy | Buy |
| May 15, 25 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Mar 31, 25 | Guggenheim | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-02
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-06-03
Corporate Changes & Voting Matters
8-K · 2026-06-02
Corporate Changes & Voting Matters
8-K · 2026-05-04
Proxy Statements
DEFA14A · 2026-04-20
Proxy Statements
PRE 14A · 2026-04-10
Headlines
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
PR Newswire · 34d ago
ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses
Insider Monkey · 40d ago
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
Motley Fool · 48d ago
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook
Simply Wall St. · 52d ago
ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says
MT Newswires · 54d ago
ADC Therapeutics S.A. Q2 2026 Earnings Call Summary
Moby · 54d ago
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ...
GuruFocus.com · 54d ago
ADC Therapeutics Q2 Earnings Call Highlights
MarketBeat · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.